X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Sun Pharma with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs MYLAN (US) - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   MYLAN
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
MYLAN
Dec-14
SUN PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs8423,862-   
Low Rs5722,722-   
Sales per share (Unadj.) Rs131.61,322.1-  
Earnings per share (Unadj.) Rs32.7159.3-  
Cash flow per share (Unadj.) Rs38.0256.4-  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs152.7657.2-  
Shares outstanding (eoy) m2,399.26378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x5.42.5 215.8%   
Avg P/E ratio x21.620.7 104.6%  
P/CF ratio (eoy) x18.612.8 145.1%  
Price / Book Value ratio x4.65.0 92.5%  
Dividend payout %10.70-   
Avg Mkt Cap Rs m1,696,8771,245,533 136.2%   
No. of employees `00017.525.0 70.1%   
Total wages/salary Rs m49,0230-   
Avg. sales/employee Rs Th18,028.320,010.2 90.1%   
Avg. wages/employee Rs Th2,798.80-   
Avg. net profit/employee Rs Th4,479.52,410.6 185.8%   
INCOME DATA
Net Sales Rs m315,784500,256 63.1%  
Other income Rs m6,232-2,916 -213.7%   
Total revenues Rs m322,016497,340 64.7%   
Gross profit Rs m100,893124,416 81.1%  
Depreciation Rs m12,64836,742 34.4%   
Interest Rs m3,99821,578 18.5%   
Profit before tax Rs m90,47963,180 143.2%   
Minority Interest Rs m0-259 0.0%   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,1162,657 456.0%   
Profit after tax Rs m78,46260,264 130.2%  
Gross profit margin %31.924.9 128.5%  
Effective tax rate %13.44.2 318.4%   
Net profit margin %24.812.0 206.3%  
BALANCE SHEET DATA
Current assets Rs m329,537439,791 74.9%   
Current liabilities Rs m178,870343,829 52.0%   
Net working cap to sales %47.719.2 248.7%  
Current ratio x1.81.3 144.0%  
Inventory Days Days7978 101.2%  
Debtors Days Days83107 77.6%  
Net fixed assets Rs m204,766115,733 176.9%   
Share capital Rs m2,39917,690 13.6%   
"Free" reserves Rs m363,9970-   
Net worth Rs m366,397248,676 147.3%   
Long term debt Rs m14,361371,498 3.9%   
Total assets Rs m614,1021,001,646 61.3%  
Interest coverage x23.63.9 601.6%   
Debt to equity ratio x01.5 2.6%  
Sales to assets ratio x0.50.5 103.0%   
Return on assets %13.48.2 164.3%  
Return on equity %21.424.2 88.4%  
Return on capital %24.813.6 182.3%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m19,6340-   
CASH FLOW
From Operations Rs m70,82265,759 107.7%  
From Investments Rs m-42,216-51,859 81.4%  
From Financial Activity Rs m-22,854-17,328 131.9%  
Net Cashflow Rs m6,107-3,428 -178.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.8 Rs / USD

Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare SUN PHARMA With: ORCHID PHARMA LTD  SANOFI INDIA  DIVIS LABORATORIES  LUPIN LTD  DR. REDDYS LAB  



Today's Market

Indian Indices Continue Downtrend; Realty Stocks Top Losers(01:30 pm)

After opening the day lower, share markets in India have continued the downtrend and are currently trading below the dotted line. Sectoral indices are trading on a negative note with stocks.

Related Views On News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)

Sep 16, 2017

We take a glimpse of Equitymaster's results from rule based investing.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Gold Imports Surge: Are People Hedging the Risk of Another Demonetisation?(Vivek Kaul's Diary)

Sep 19, 2017

Imports of the yellow metal have surged big time this year.

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

A Little-Known Japanese Secret for Compounding Wealth

Sep 22, 2017

What Warren Buffett and Benjamin Graham have in common with a little known Japanese secret.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 25, 2017 03:18 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - GLENMARK PHARMA COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS